Fulcrum Therapeutics, Inc. (FULC) — Executive Compensation
Fiscal year ended December 2025
This page summarizes Fulcrum Therapeutics, Inc. (FULC) named executive officer compensation from the most recent SEC DEF 14A proxy statement. Alex Sapir (CEO) received $0 in reported total compensation@if($peoPaid !== null), with $0 "actually paid" under the SEC pay-versus-performance rule. @endif Total shareholder return for the period was 15,536.00.
Frequently asked questions
Who is the CEO of FULC and how much are they paid?
Executive compensation for Fulcrum Therapeutics, Inc. is disclosed in the company's SEC DEF 14A proxy statement. When available, the latest CEO total compensation figure will appear on this page.
What is included in executive compensation?
SEC Summary Compensation Table figures include base salary, cash bonuses, stock awards (grant-date fair value), option awards, non-equity incentive plan compensation, pension value changes, and all other compensation. "Actually Paid" compensation follows the newer SEC pay-versus-performance rule and reflects realized value.
What is pay-versus-performance?
The SEC pay-versus-performance disclosure requires companies to show the relationship between executive pay "actually paid" and total shareholder return (TSR) over recent fiscal years, so investors can evaluate pay alignment.